by BioMed Central

A new method to produce vaccines that have a longer shelf-life, are cheaper and can be stored without the need for cooling is being presented in the open access journal BMC Biotechnology.

Vaccines currently need to be refrigerated during transport and storage and have a short shelf-life, in some cases as little as a few months. This can be a problem in low-income countries and remote areas with no electricity. Some vaccines also rely on additional pharmacological or immunological substances, called adjuvants, to boost their desired immune response, which may have unwanted side-effects, such as allergies.

Luis Vaca, at Universidad Nacional Autonoma de Mexico, the corresponding author said: “The vaccines that are currently available require constant cold storage, meaning they rely on a temperature-controlled supply chain, which constitutes over 80% of their cost. We have developed a novel technology to produce vaccines which require no refrigeration and have a shelf life of many years. These vaccines could be transported to regions of the world without electricity and refrigeration.”

Vaca and a team of researchers adapted a strategy used by insect viruses that allows them to survive outside of their host for extended periods of time. A key component of this strategy is a protein known as polyhedrin that forms crystals around the virus, protecting it from the environment. Previous research by the authors showed that a short sequence of the first 110 amino acids that make up polyhedrin (PH(1-110)) maintains the ability of the full length protein to form crystals, even when other proteins, including viruses, are attached to it.

Combining part of porcine circovirus, which can cause disease in pigs, with PH(1-110) has been shown to prompt the production of antibodies in vaccinated pigs. However, the exact characteristics of the particles that form after combining PH(1-110) and a virus, including thermostability (the ability to withstand heat), have not been investigated, and neither has the strength of a possible immune response.

To investigate these characteristics and the possible usefulness of PH(1-110) as a vaccinecarrier, the authors combined PH(1-110) with the green fluorescent protein (GFP), which normally generates a weak immune response. Once PH(1-110) had formed polyhedrin crystals around the protein, the authors injected mice with the PH(1-110)GFP crystals to evaluate the immune response.

They found that mice injected with PH(1-110)GFP produced anti-GFP antibodies and showed a strong immune response, similar to one observed in mice injected with GFP and an adjuvant. As GFP on its own does not create a strong immune response, an adjuvant would normally be needed. Anti-GFP antibodies remained in the blood of vaccinated mice after 24 weeks, indicating the production of a lasting immune response.

The authors also found that PH(1-110)GFP particles stored as dry powder at room temperature still generated antibodies when they were used to vaccinate mice after up to twelve months of storage. The results suggest that PH(1-110) could enable the production of thermostable vaccines that generate a sufficient immune response without the need for an adjuvant, or refrigeration.

Luis Vaca said: “As PH(1-110) could be paired with any protein, our technology opens up the possibility of reducing the cost of conservation and distribution of vaccines by about 80% – the cost of the temperature-controlled supply chain. Pharmaceutical companies could maintain their profits, but the consumer would pay less, reducing the cost of vaccination in low-income countries significantly.”